Page last updated: 2024-08-21

indazoles and Cancer of Lung

indazoles has been researched along with Cancer of Lung in 193 studies

Research

Studies (193)

Timeframe	Studies, this research(%)	All Research%
pre-1990	8 (4.15)	18.7374
1990's	19 (9.84)	18.2507
2000's	9 (4.66)	29.6817
2010's	109 (56.48)	24.3611
2020's	48 (24.87)	2.80

Authors

Authors	Studies
Awad, MM; Dowlati, A; Dy, GK; Haque, B; Iannotti, N; Iyer Singh, N; Lu, S; Ramalingam, SS; Spigel, DR; Stinchcombe, TE; Tang, Y; Teslenko, I; Thara, E	1
Osman, HM; Tuncbilek, M	1
Byun, JH; Cho, HJ; Choi, E; Han, DG; Jung, IH; Park, T; Seo, SW; Yoon, IS	1
Agoni, C; Ibrahim, MAA; Issahaku, AR; Manimbulu, N; Salifu, EY; Soliman, MES	1
Djebli, N; González-Sales, M; Jaminion, F; Meneses-Lorente, G; Mercier, F	1
Ahn, MJ; Bazhenova, L; Chawla, SP; Chen, D; Chiu, CH; Cho, BC; De Braud, F; Demetri, GD; Drilon, A; Dziadziuszko, R; Fakih, M; Goto, K; Heinzmann, S; John, T; Lee, J; Lin, JJ; Liu, SV; Patel, MR; Pitcher, B; Rolfo, C; Seto, T; Siena, S; Wilson, TR	1
Artemov, A; Druy, A; Hwang, EI; Imyanitov, E; Karachunsky, A; Kislyakov, A; Maschan, A; Novichkova, G; Packer, RJ; Panferova, A; Papusha, L; Salnikova, E; Valiakhmetova, A; Zaytseva, M	1
Bartolome, L; Camidge, DR; Cappelleri, JC; Daniele, P; Groff, M; Iadeluca, L; Tremblay, G; Usari, T; Wilner, K; Wiltshire, R	1
Barlesi, F; Chang, CW; Choeurng, V; Dennis, L; Doebele, RC; Drilon, A; Dziadziuszko, R; Hung, T; Li, M; Riehl, T; Simmons, B; Skoletsky, J; Wang, K; Wilson, TR; Woodhouse, R; Wu, C	1
Cui, Y; Du, F; Feng, L; Huang, W; Li, B; Yin, X	1
Abdelbaki, MS; Armstrong, AE; Basu, EM; Bergthold, G; Cardenas, A; Caron, H; Cash, T; Chohan, S; Chow Maneval, E; Corradini, N; Desai, AV; Devlin, C; Farid-Kapadia, M; Foster, JH; Fox, E; Gajjar, A; Gauvain, K; Hutchinson, KE; Macy, ME; Maese, L; Marshall, LV; Meneses-Lorente, G; Pratilas, CA; Robinson, GW; Sabnis, AJ; Shusterman, S; Weiss, BD; Whipple, NS; Yoon, J	1
Chen, L; Jiang, Q; Li, H; Li, M	1
Chen, C; Li, CG; Li, Y; Liu, HL; Wang, CL; Zhang, ZF	1
Mahapatra, M; Mal, S; Malik, U; Mishra, A; Paidesetty, SK; Pal, D	1
Fujita, N; Gong, B; Hanzawa, H; Hata, AN; Isoyama, T; Iwasaki, S; Kagoshima, Y; Kamai, Y; Katayama, R; Kiga, M; Koike, S; Miyamoto, M; Nakao, N; Nishio, M; Oh-Hara, T; Seto, Y; Shaw, AT; Shimizu, Y; Takeda, Y; Togashi, N; Tominaga, Y; Watanabe, K; Yanagitani, N; Yoda, S	1
Lassen, U	1
Ahn, MJ; Arkenau, HT; Barlesi, F; Chae, YK; Chiu, CH; Cho, BC; Chow-Maneval, E; Chung, CH; Cui, N; de Braud, F; Doebele, RC; Drilon, A; Dziadziuszko, R; Eng, S; Goto, K; John, T; Johnson, A; Karapetis, CS; Kim, SW; Krebs, MG; Li, YC; Lin, CC; Murakami, H; Ohe, Y; Otterson, GA; Patel, MR; Prenen, H; Riehl, T; Rolfo, C; Seto, T; Shaw, AT; Siena, S; Simmons, B; Tan, DSW; Wilson, TR; Wolf, J	1
Giuffrida, D; Puglisi, C; Puliafito, I; Russo, A; Sciacca, D	1
Hu, H; Hu, MN; Li, JY; Miao, XK; Mou, LY; Xu, JJ; Yang, WL; Zhang, JY; Zhang, XW; Zhou, TX	1
Cerea, G; Marrapese, G; Pizzutilo, EG; Sartore-Bianchi, A; Siena, S; Tosi, F	1
Koh, Y; Oyanagi, J; Serizawa, M; Shukuya, T; Watanabe, M; Yamamoto, N	1
Hayashi, M; Makino, T; Mizawa, M; Mori, N; Shimizu, T	1
Carlson, JJ; Roth, JA; Sullivan, SD; Williamson, T; Xia, F	1
Adhikary, R; Hussain, T; Khandelwal, R; Nayarisseri, A; Singh, SK	1
Arkenau, HT; Coleman, N; Popat, S; Welsh, L; Yousaf, N	1
Ahn, JS; Ahn, MJ; Jung, HA; Lee, J; Lee, SH; Park, K; Park, S; Sun, JM	1
Battistone, B; Garrido-Laguna, I; Ghazi, P; Kinsey, CG; McMahon, M; Parkman, GL; Scherzer, MT; Schuman, S; Truong, A; Vaishnavi, A	1
Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J	1
Anyaegbu, G; Bentley, H; Bulusu, VR; Hatcher, H; Horan, G; Watkins, J; Wong, HH	1
Arizio, F; Bironzo, P; Listì, A; Novello, S; Passiglia, F; Righi, L; Scagliotti, GV; Volante, M	1
Chen, Y; Huang, K; Huang, Y; Li, Y; Liu, X; Petersen, RB; Quan, C; Wang, Q; Wang, X; Yang, D; Zheng, L	1
Antoniou, M; Freund, R; Ogale, S; Zerbini, CEH	1
Chen, C; Chen, J; Gong, H; Li, W; Li, Y; Liu, C; Liu, H; Liu, M; Shi, R; Yuan, Y; Zhang, H; Zhang, Z	1
Araujo, JM; Gomez, AC; Pinto, JA; Raez, LE; Rolfo, C	1
Adachi, J; Araki, M; Friboulet, L; Fujita, N; Katayama, K; Katayama, R; Kukimoto-Niino, M; Kutkowska, J; Ma, B; Maruyama, K; Mizuta, H; Nishio, M; Oh-Hara, T; Okada, K; Okuno, Y; Sagae, Y; Sasakura, Y; Shirouzu, M; Simizu, S; Takagi, S; Takemoto, A; Tamai, K; Watanabe, K; Yanagitani, N	1
Ahn, MJ; Barlesi, F; Chen, D; Chiu, CH; Cho, BC; Day, BM; De Braud, F; Doebele, RC; Drilon, A; Dziadziuszko, R; Farago, AF; Karapetis, CS; Krebs, MG; Li, YC; Lin, CC; Liu, SV; Patel, MR; Siena, S; Wilson, TR	1
Antoniou, M; Bennett, I; Blay, JY; Hong, D; Krebs, MG; Le Tourneau, C; Veronese, L	1
Delgado, J; Enzmann, H; Josephson, F; Melchiorri, D; Migali, C; Pean, E; Pignatti, F	1
Gao, Y; Gong, Y; Jiang, X; Li, J; Luo, Y; Xie, C; Zeng, Z; Zhang, J; Zhang, N	1
Frampton, JE	1
Maruo, K; Tabata, H; Takagi, Y; Takahashi, A; Takayanagi, A	1
Higuchi, T; Hoffman, RM; Kanaya, F; Miyake, K; Nishida, K; Oshiro, H; Sugisawa, N; Tome, Y	1
Ai, X; Chen, G; Cui, J; Ding, C; Dong, X; Gao, B; He, J; Hu, C; Hu, X; Huang, C; Jiang, L; Li, J; Li, X; Li, Y; Liao, W; Liu, A; Liu, C; Liu, X; Liu, Z; Lu, S; Ma, Z; Pan, Y; Shi, J; Song, Y; Wang, K; Wang, M; Wang, W; Xiong, J; Yang, N; Zhang, B; Zhang, D; Zhang, H; Zhang, X; Zhang, Y; Zhao, J; Zhou, J	1
Ahn, MJ; Barlesi, F; Chen, D; Conley, A; Demetri, G; Doebele, R; Drilon, A; Kapre, A; McCallum, S; Osborne, S; Paz-Ares, L; Rolfo, C; Seto, T; Siena, S; Wolf, J	1
Aiba, H; Hayashi, K; Kawaguchi, Y; Kimura, H; Miwa, S; Murakami, H; Nakanishi, R; Okamoto, H; Saito, S; Sakai, T; Tatematsu, T; Yamada, S	1
Beydoun, N; Cooper, W; Kasherman, L; Liu, Q; Lu, M; Lynch, J; Woodford, R	1
Chen, DH; Fonseca, M; Ghosh, AK; Walker, JM	1
Domoto, H; Hashiguchi, MH; Hiroshima, Y; Kagyo, J; Kato, T; Matsuzaki, T; Nakahara, Y; Sato, T; Shiomi, T; Watanabe, R; Yokose, T	1
Besse, B; Bria, E; Facchinetti, F; Friboulet, L; Minari, R; Rossi, G; Soria, JC; Tiseo, M	1
Ancell, K; Berlin, JD; Cardin, DB; Chan, E; Goff, LW; Smith, SJ; Whisenant, JG; Ye, F	1
Agelaki, S; Fountzilas, G; Georgoulias, V; Hartabilas, E; Karavassilis, V; Katsaounis, P; Kentepozidis, N; Koinis, F; Kotsakis, A; Messaritakis, I; Peroukidis, S; Samantas, E; Varthalitis, II	1
Bang, YJ; Hamid, O; Kang, YK; Kim, TM; Michael, M; Park, YS; Raddad, E; Tate, SC; Thornton, D; Tie, J	1
Adachi, S; Kato, I; Okamoto, T; Saida, S; Umeda, K	1
Ai, J; Chen, H; Chen, X; Gao, Y; Geng, M; He, Y; Li, C; Liu, H; Peng, X; Wang, J; Wang, Y; Zheng, M; Zhu, W	1
Benson, C; Freivogel, KW; Gelderblom, H; Grignani, G; Jobanputra, M; Judson, IR; Katz, D; Manson, SC; Merimsky, O; Mungul, A; Sanfilippo, R; Stein, D	1
George, TJ; Hromas, R; Jaiswal, AS; Jones, D; Najmunnisa, N; Sidhu, GS; Srinivasan, G; Wilcoxen, K; Williamson, EA	1
Davidson, D; Jones, RL; Katz, D; Loggers, ET; Pollack, SM; Rodler, ET	1
Kang, MJ; Lee, JH; Yun, HH	1
Adjei, AA; Bahleda, R; Besse, B; Dy, GK; Ferte, C; Groen, HJM; Lin, W; Morrissey, K; Planchard, D; Schutzman, JL; Shankar, G; Soria, JC; Ware, J; Zhou, J	1
Chen, J; Feng, Z; Gao, J; Gatza, ML; Haffty, BG; Hu, W; Huang, S; Khella, CA; Liu, J; Tomsky, K; White, E; Wu, H; Xia, D; Xie, H; Yue, X; Zhang, C; Zhao, Y	1
'Aho, T; Armitage, JN; Eisen, T; Fife, K; Klatte, T; Matakidou, A; Riddick, AC; Sachdeva, M; Stewart, GD; Welsh, SJ	1
Liu, D; Ren, H; Sun, X; Wang, J; Wang, M; Xiao, G; Xu, C; Zhang, B; Zhang, J	1
Ahn, JS; Ahn, MJ; Jung, SH; Kim, BS; Kim, HG; Lee, KH; Lee, SH; Min, YJ; Park, K; Sun, JM; Yi, SY; Yun, HJ	1
Qi, Y; Qiao, Q; Qin, X; Song, Q; Wu, T; Yang, C; Zhang, Z	1
Chorner, PM; Moorehead, RA	1
Arbour, KC; Riely, GJ	1
Burris, HA; Daniel, DB; Finney, L; Gian, VG; Greco, FA; Hainsworth, JD; Heymach, JV; Lipman, AJ; Shih, KC; Spigel, DR; Waterhouse, DM	1
Iida, S; Joh, T; Kanamori, T; Kataoka, H; Kinoshita, S; Komatsu, H; Kondo, M; Kuroda, J; Mori, Y; Takemoto, M	1
Bian, X; Cheng, H; Gao, J; Li, T; Liu, P; Luo, F; Rui, C; Usman, MW; Zheng, T	1
Fujita, M; Kuroda, T; Mukai, M; Nakai, Y; Nishimura, K; Oka, T; Shioyama, W; Takada, M; Yasui, T	1
Ahmed, T; Balagani, A; Grosu, HB; Muhammad, HA; Ost, DE; Sabath, B; Vakil, E; Vial, MR	1
Davis, RL; Desai, A; Lara-Gonzalez, P; Oegema, K; Shiau, AK	1
Cescon, DW; Chen, Y; Dmitrovsky, E; Kawakami, M; Kurie, JM; Liu, X; Mak, TW; Mino, B; Mustachio, LM; Rodriguez-Canales, J; Roszik, J; Silvester, J; Thu, KL; Villalobos, PA; Wistuba, II; Zheng, L	1
Berglund, UW; Blackhall, F; Chester, CPE; Dive, C; Frese, KK; Gorgoulis, VG; Gulati, S; Helleday, T; Kalderen, C; Khandelwal, G; Lallo, A; Miller, C; Pateras, IS; Pham, TM; Schenk, MW	1
Biemans, R; Bussink, J; Dubois, LJ; Meijer, TWH; Peeters, WJM; Span, PN; van Gisbergen, MW; Venhuizen, JH	1
Ebi, H; Ikeda, H; Kotani, H; Ohtsubo, K; Takeuchi, S; Tanimoto, A; Yamada, T; Yamashita, K; Yano, S	1
Ai, J; Chen, D; Chen, L; Chen, Y; Dai, Y; Gao, Y; Geng, M; Guo, Z; Ji, Y; Jiang, Y; Peng, X; Shen, J; Shi, H; Wang, Q; Wang, X; Xiong, B	1
Jeon, SY; Lee, NR; Yim, CY	1
Bando, M; Endo, S; Hagiwara, K; Kurosaki, A; Mato, N; Niki, T; Onuki, T; Sakamoto, N; Takigami, A; Tetsuka, K; Yamasawa, H	1
Ak, G; Bozkaya, ÜF; Hamarat Şanlıer, Ş; Tanıyan, G; Ünal, A; Yıldırım, Y; Yıldız Türkyılmaz, G; Yılmaz, H	1
Chen, Z; Li, Z; Wang, X; Xia, W; Yang, X; Zeng, Q	1
Chang, AC; Chen, G; Cheng, G; Hardy, M; Kalyanaraman, B; Kresty, L; Lee, Y; Myers, CR; Ouari, O; Pan, J; Weh, K; You, M; Zhang, Q; Zielonka, J; Zielonka, M	1
Ahn, JS; Ahn, MJ; Bae, YH; Ku, BM; Lee, KY; Lee, SH; Park, K; Sun, JM	1
Al-Salama, ZT; Keam, SJ	1
King, JW; Lee, SM	1
Cohen, JE; Cohen, Y; Doviner, V; Goldshmidt, H; Katz, D; Orevi, M; Peylan-Ramu, N; Rubinstein, R; Zick, A	1
Belmont, LD; Fairbrother, WJ; Hong, R; Lee, LB; Nannini, MA; Price, S; Sampath, D; Savy, PP; Settleman, J; Tan, N; Williams, K; Wong, M; Yue, P	1
Kai, F; Nagata, M; Ozono, S; Sugiyama, T; Takayama, T	1
Beauchamp, EM; Getz, G; Gray, NS; Haddad, RI; Hammerman, PS; Hayes, DN; Jung, J; Liao, RG; Liu, Q; Meyerson, M; Pedamallu, CS; Pugh, TJ; Sivachenko, A; Tchaicha, J; Wilkerson, MD; Wong, KK	1
André, F; Ashworth, A; Bajrami, I; Dorvault, N; Elliott, R; Fontebasso, Y; Friboulet, L; Lord, CJ; Olaussen, KA; Postel-Vinay, S; Soria, JC	1
Bi, C; Credille, KM; Donoho, GP; Manro, JR; Peek, VL; Walgren, RA; Wijsman, JA; Wu, W; Yan, L; Yan, SB	1
Bian, XC; Feng, HL; Li, ZW; Liu, YQ; Liu, YY; Yang, ZL	1
Bosenberg, M; De, SK; Feng, Y; Kluger, H; Lazova, R; Li, JL; Pellecchia, M; Rickert, R; Ronai, ZA; Ruller, C; Scortegagna, M	1
Cai, P; Chen, W; Fang, X; Gao, Z; Gu, Y; Shu, Y; Sun, Y; Tao, F; Xu, Q; Yuan, H; Zhang, X	1
Abrams, JS; Conley, BA; Freidlin, B; Korn, EL; McShane, LM; Polley, MY	1
Arif, Q; Hasina, R; Husain, AN; Kawada, I; Mueller, J; Salgia, R; Smithberger, E; Vokes, EE	1
Chow, WA; Eroglu, Z; Kim, J; Wilczynski, S	1
Bycott, P; Chen, C; Chmielowska, E; de Besi, P; Havel, L; Ingrosso, A; Kim, S; Olszanski, AJ; Popat, S; Sawrycki, P; Schiller, JH; Swieboda-Sadlej, A; Twelves, C; Williams, JA	1
Calogero, A; Ciccone, AM; De Falco, E; Ibrahim, M; Menna, C; Pacini, L; Petrozza, V; Puca, R; Rendina, EA; Ruggieri, P; Scafetta, G	1
Besse, B; Bosquee, L; Chouaid, C; Felip, E; Lechevalier, T; Lianes-Barragán, P; Mellemgaard, A; Ottesen, LH; Paul, EM; Reck, M; Ruiz-Soto, R; Scagliotti, GV; Sigal, E; von Pawel, J	1
Attia, S; Caracciollo, JT; Conley, AP; Koplin, S; Reed, DR; Webber, NP	1
Bendell, J; Burris, HA; Dowlati, A; Infante, JR; Jones, SF; Kane, MP; Levinson, KT; Stein, MN; Suttle, AB; Tan, AR	1
Carlson, DM; Horai, T; Horiike, A; Horinouchi, H; Kaneda, H; McKee, MD; Nakagawa, K; Nishio, M; Nokihara, H; Ohyanagi, F; Okabe, T; Tamura, T; Terashima, M; Xiong, H; Yamamoto, N	1
Agate, L; Boucher, A; Bycott, P; Chen, C; Cohen, EE; Ingrosso, A; Jarzab, B; Kane, MA; Kim, S; Licitra, L; Locati, LD; Ou, SH; Pithavala, YK; Qin, S; Wirth, LJ	1
Bonner, JA; Buchsbaum, DJ; Grizzle, WE; Li, Y; Meredith, RF; Raisch, KP; Spencer, SA	1
Bridges, KA; Buchholz, TA; Buser, CA; Liu, H; Meyn, RE; Toniatti, C	1
Boysen, A; Lücke, A; Rossen, P; Safwat, A	1
Dhruva, N; Grilley-Olson, J; Ivanova, A; Socinski, MA; Stinchcombe, TE; Villaruz, LC; Weiss, JM	1
Bourlon, MT; Kessler, ER	1
Nishiyama, T; Niwa, N; Ozu, C; Saito, S; Yagi, Y	1
Ames, E; Borys, D; Canter, RJ; Chen, M; Grossenbacher, SK; Li, CS; Mac, S; Monjazeb, AM; Murphy, WJ; Sayers, TJ; Smith, RC; Tellez, J	1
Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L	1
Chryssidis, S; Cohen, L; Kotasek, D; Neuhaus, S	1
Axelrod, R; Barrios, CH; Belani, CP; Carlson, DM; Devanarayan, V; Gorbunova, VA; Kolman, P; Makhson, A; McKee, MD; McKeegan, EM; Owonikoko, TK; Pereira, JR; Pittman, KB; Qian, J; Qin, Q; Ramalingam, SS; Ricker, JL; Segalla, JG; Shtivelband, M; Soo, RA; Srkalovic, G	1
Han, S; Hyun, C; Jo, J; Kim, JH; Kim, JY; Kim, W; Kwon, J; Rhee, J	1
Ali, SM; Morris, JC; Pal, SK; Palma, N; Ross, JS	1
Bar-Sela, G; Keidar, Z; Naroditsky, I; Semenisty, V	1
Baas, P; Blackhall, F; Cufer, T; Gaafar, R; Georgoulias, V; Hasan, B; Hennig, I; Menis, J; Montes, A; O'Brien, ME; Popat, S; Schmid-Bindert, G; Surmont, V; Woll, PJ	1
Choi, EY; Kim, S; Kwon, TK; Lee, J; Park, JW; Shin, KC	1
Fujisawa, M; Harada, K; Imai, S; Miyake, H	1
Kim, D; Kwon, A; Lee, BY; Min, KH; Nguyen, HK; Song, J; Suh, W; Yoo, J	1
Ansell, PJ; Bhathena, A; Carlson, DM; Chakravartty, A; Chan, S; Chandran, RK; Davis, G; Devanarayan, V; Dowell, BL; Gawel, SH; McKee, MD; McKeegan, EM; Ramalingam, SS; Ricker, JL	1
Abramova, E; Atochina-Vasserman, EN; Ersumo, NT; Gow, AJ; Guo, CJ; James, ML; Krymskaya, VP; Liu, AY; Rue, R	1
Bauer, TM; Chow-Maneval, E; Costa, DB; Drilon, A; Farago, AF; Hornby, Z; Iafrate, AJ; Jackman, D; Le, LP; Li, GG; Lim, JE; Liu, SV; Luo, D; Multani, PS; Muzikansky, A; Ou, SH; Patel, M; Shaw, AT; Zheng, Z	1
Izumi, K; Konaka, H; Mizokami, A; Namiki, M; Yaegashi, H	1
Abdollahi, A; Alves, F; Chiblak, S; Fuchs, B; Jannasch, K; Kleeff, J; Lindner, T; Matzke-Ogi, A; Mier, W; Morton, J; Orian-Rousseau, V; Ponta, H; Sansom, O; Schwager, C; Shatirishvili, M; Tawk, B; Warth, A	1
Gillessen, S; Hader, C; Rothermundt, C	1
Bortlicek, Z; Buchler, T; Dusek, L; Fiala, O; Honzirkova, M; Kubackova, K; Melichar, B; Pavlik, T; Poprach, A; Slaby, O; Svoboda, M; Veskrnova, V; Vyzula, R; Zemanova, M	1
Baas, P; Buikhuisen, WA; Griffioen, AW; Korse, CM; Scharpfenecker, M; van Tinteren, H	1
Bertino, E; Haglund, K; Haraldsdottir, S; Kaffenberger, B; Shah, MH	1
Ardini, E; Avanzi, N; Banfi, P; Borgia, AL; Bossi, R; Buffa, L; Canevari, G; Ceriani, L; Colombo, M; Corti, L; Donati, D; Fasolini, M; Felder, E; Fiorelli, C; Fiorentini, F; Galvani, A; Isacchi, A; Magnaghi, P; Marchionni, C; Menichincheri, M; Nesi, M; Orrenius, C; Orsini, P; Panzeri, A; Perrone, E; Pesenti, E; Rusconi, L; Saccardo, MB; Vanotti, E	1
Atreya, CE; Bergsland, EK; Cives, M; Coppola, D; Hwang, J; Kelley, RK; Morse, B; Nickerson, M; Strosberg, JR; Valone, T; Venook, A; Weber, T	1
Grünwald, V; Kalanovic, D; Lin, X; Simantov, R	1
Demizu, Y; Futani, H; Mohri, T; Okimoto, T; Sakagami, M; Terada, T; Tsukamoto, Y; Uwa, N	1
Ikezawa, Y; Mizugaki, H; Nishimura, M; Oizumi, S; Sakakibara-Konishi, J	1
Agrafiotis, AC; Grosdidier, G; Prieto, M; Rios, M; Siat, J; Verhaeghe, JL	1
Ebina, Y; Miyamoto, T; Nagamata, S; Nishijima, M; Yamada, H; Yamano, Y	1
Campanario, R; Juárez, A; Saiz, R; Soto, M	1
Barr, M; Cuffe, S; Finn, S; Gately, K; Heavey, S; Leonard, N; McVeigh, N; Nicholson, S; O'Byrne, K; Ryan, R; Young, V	1
Amantea, MA; Chen, Y; Garrett, M; Ingrosso, A; Mould, DR; Pithavala, YK; Taylor, T	1
Abe, K; Funakoshi, Y; Ito, N; Kawata, S; Moriuchi, H; Okada, M	1
Bauer, S; Baumann, M; Engel, J; Ketzer, J; Keul, M; Lategahn, J; Mühlenberg, T; Rauh, D; Schultz-Fademrecht, C; Tomassi, S; Tumbrink, HL	1
Döme, B; Magyar, M	1
Hu-Lowe, DD; Kuhnert, F; Kuo, CJ; Mancuso, MR; McDonald, DM; Sennino, B; Tabruyn, SP	1
Bycott, P; Kim, S; Larson, T; Liau, K; Limentani, S; Olszanski, AJ; Ou, SH; Sandler, A; Schiller, JH; Vokes, E; von Pawel, J	1
Kelly, RJ; Rixe, O	1
Barrios, CH; Chen, M; Davis, ID; Gladkov, OA; Hawkins, RE; Kavina, A; Lee, E; Mardiak, J; McCann, L; Pandite, L; Roychowdhury, DF; Salman, P; Sternberg, CN; Szczylik, C; Wagstaff, J; Zarbá, JJ	1
Altorki, N; Bordogna, W; Heymach, JV; Nikolinakos, PG; Ottesen, LH; Rajagopalan, D; Tran, HT; Yan, S; Yankelevitz, D	1
Ratain, MJ	1
Altorki, N; Bauer, T; Felip, E; Grannis, FW; Guarino, MJ; Gurpide, A; Huff, A; Lane, ME; Lee, PC; Mitchell, JD; Ottesen, LH; Pass, H; Peylan-Ramu, N; Reeves, A; Roychowdhury, DF; Swann, RS; Tachdjian, S; Yankelevitz, DF	1
Besse, B; Carlson, DM; Gandara, DR; Goss, GD; Gupta, N; Hanna, NH; Hensing, T; Lee, C; Mazieres, J; Pradhan, R; Qian, J; Qin, Q; Ricker, JL; Salgia, R; Scappaticci, FA; Soo, RA; Tan, EH; Thertulien, R; Wertheim, M; Yang, JC	1
Bellenger, J; Shen, YZ; Wang, F; Zhang, LN; Zhang, XH; Zou, ZQ	1
Ang, KK; Buchholz, T; Buser-Doepner, C; Mason, KA; Mathur, A; Milas, L; Toniatti, C; Valdecanas, D; Wang, L	1
Goozner, M	1
B Cohen, R; Olszanski, AJ; Patson, B	1
Albert, DH; Day, M; Fox, GB; Hickson, JA; Luo, Y; Mudd, SR; Refici-Buhr, M; Reuter, DR; Tapang, P; Voorbach, MJ	1
Ansell, P; Carlson, DM; Carr, BI; Chen, PJ; Dowell, B; Gill, S; Knox, JJ; McKeegan, EM; Pedersen, M; Qian, J; Qin, Q; Ricker, JL; Scappaticci, FA; Toh, HC; Yong, WP	1
Arriola, E; Cohen, RB; De Castro Carpeño, J; Herbst, RS; Kim, S; Kozloff, MF; Krzakowski, M; Martin, LP; Olszanski, AJ; Rado, TA; Rosbrook, B; Samuel, TA; Tarazi, J; Tortorici, M	1
Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S	1
Araki, N; Itoh, K; Naka, N; Tanaka, T; Wakamatsu, T; Yoshikawa, H; Yoshioka, K; Yui, Y	1
Amler, LC; Brachmann, RK; Fridlyand, J; Friedman, LS; Hampton, GM; Haverty, PM; Huw, L; Koeppen, H; Lackner, MR; Mohan, S; O'Brien, C; Pandita, A; Ross, L; Sampath, D; Shames, DS; Spoerke, JM	1
Carlini, P; Cognetti, F; Di Cosimo, S; Fabi, A; Ferretti, G; Papaldo, P	1
Konovalova, NP	1
Ashok Kumar, B; Gururaj, S; Lingaiah, BP; Narsaiah, B; Parthasarathy, T; Shireesha, B; Sridhar, B; Yakaiah, T	1
Chen, CJ; Chung, JG; Hsu, MH; Huang, LJ; Kuo, SC; Lee, FY; Teng, CM; Yamori, T	1
Bolte, O; Bukowski, RM; Bycott, P; Freddo, J; Hudes, GR; Kim, S; Liau, KF; Michaelson, MD; Motzer, RJ; Rini, BI; Rixe, O; Trask, PC; Wilding, G	1
Caputo, A; Silvestrini, B	1
Brunner, KW; Cavalli, F; Goldhirsch, A; Joss, RA; Mermillod, B	1
Ciottoli, GB; De Gregorio, M; Kokron, O; Maca, S; Scheiner, W	1
Buccheri, G; Ferrigno, D	1
Nardini, S	1
Evans, G; McCunniff, AJ; Paggiarino, DA; Scarantino, CW; Young, CW	1
Berni, F; Calzavara, MP; Cattaneo, MT; D'Adda, D; Filipazzi, V; Frontini, L; Isa, L; Legnani, W; Rho, B; Scapaticci, R	1
Buccheri, G; Ferrigno, D; Rosso, A	1
Mori, K; Suga, Y; Takahashi, T; Tominaga, K	1
Brancaccio, L; Carnicelli, P; Cioffi, R; Comella, P; De Cataldis, G; Ianniello, GP; Lombardi, A; Maiorino, A; Scarpati, MD; Tinessa, V	1
Bianco, A; Bilancia, D; Carpagnano, F; Cioffi, R; Comella, G; Comella, P; De Cataldis, G; De Lena, M; Di Rienzo, G; Frasci, G; Lorusso, V; Maiorino, L; Manzione, L; Natale, M; Nicolella, G; Pacilio, C; Panza, N	1
Dahlén, SE; Larsson, L; Sydbom, A	1
Kimura, I; Kiura, K; Ohnoshi, T; Segawa, Y; Shibayama, T; Tabata, M; Takigawa, N; Ueoka, H	1
Christoffel, V; Gatzemeier, U; Lücker, PW; Picollo, R; Toomes, H; Ulmer, J	1
Eble, M; Flentje, M; Hör, A; Latz, D; Wannenmacher, M	1
Contu, A; Deriu, A; Olmeo, NA; Ortu, S; Paga, C; Pani, P	1
Cionini, L	1
Cavalli, F; Gatzemeier, U; Häussinger, K; Kaukel, E; Koschel, G; Martinelli, G; Neuhauss, R; von Pawel, J	1
Hardy, JR; Jones, AL; Newell, DR; Smith, IE	1
Canova, N; Casadio, M; Guaraldi, M; Lelli, G; Pannuti, F	1
Button, D; Catanese, B; Hardy, J; Jenns, K; Mansi, J; Newell, DR; Picollo, R; Smith, IE	1
Ciottoli, GB; De Gregorio, M; Kokron, O; Maca, S	1
Bagatella, M; Bonardi, G; Calciati, A; Donadio, M; Giaccone, G; Maestroni, F	1
Albera, C; Gozzelino, F; Pescetti, G; Scagliotti, GV	1
Band, P; Murray, N; Shah, A	1
Ambesi Impiombato, F; Antilli, A; Ciottoli, GB; De Gregorio, M; Del Vecchio, MR; Gallo-Curcio, C; Rinaldi, M; Tonachella, R; Tropea, F; Verturo, I	1
Ciottoli, GB; De Gregorio, M; De Luca, B; Greco, S; Magnani, F; Marletta, F; Palmucci, T; Patanè, C; Privitera, G; Tafuri, G	1

Reviews

23 review(s) available for indazoles and Cancer of Lung

Article	Year
Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusionpositive, Recurrent or Advanced Solid Tumors. Current medicinal chemistry, 2022, Volume: 29, Issue:15 Topics: Adult; Benzamides; Child; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases	2022
Entrectinib, a new multi-target inhibitor for cancer therapy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 150 Topics: Adult; Benzamides; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases	2022
A review on synthetic strategy, molecular pharmacology of indazole derivatives, and their future perspective. Drug development research, 2022, Volume: 83, Issue:7 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms	2022
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy. Expert review of anticancer therapy, 2020, Volume: 20, Issue:5 Topics: Animals; Benzamides; Carcinoma, Non-Small-Cell Lung; Disease Progression; Gene Fusion; Gene Rearrangement; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins	2020
Evaluating entrectinib as a treatment option for non-small cell lung cancer. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:16 Topics: Administration, Oral; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Treatment Outcome	2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses	2021
Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date. Hematology/oncology and stem cell therapy, 2021, Volume: 14, Issue:3 Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Indazoles; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins	2021
The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearr ESMO open, 2021, Volume: 6, Issue:2 Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Gene Fusion; Humans; Indazoles; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Receptors, Amino Acid	2021
Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC. Drugs, 2021, Volume: 81, Issue:6 Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptor, trkA	2021
Disseminated intravascular coagulation complicating diagnosis of ROS1-mutant non-small cell lung cancer: A case report and literature review. Thoracic cancer, 2021, Volume: 12, Issue:17 Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Disseminated Intravascular Coagulation; Female; Humans; Indazoles; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins	2021
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition. Cancer treatment reviews, 2017, Volume: 55 Topics: Aminopyridines; Anilides; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Molecular Diagnostic Techniques; Oncogene Fusion; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Pyrimidines; Sulfones	2017
Entrectinib: First Global Approval. Drugs, 2019, Volume: 79, Issue:13 Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors	2019
Axitinib for the treatment of advanced non-small-cell lung cancer. Expert opinion on investigational drugs, 2013, Volume: 22, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Humans; Imidazoles; Indazoles; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Survival Rate	2013
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Hemorrhage; Humans; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Ramucirumab; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A	2015
Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option: case report and review of anti-angiogenic treatment options. BMC cancer, 2015, May-13, Volume: 15 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Female; Hemangioendothelioma, Epithelioid; Humans; Immunohistochemistry; Indazoles; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome	2015
[Tumor vasculature as a therapeutic target in non-small cell lung cancer]. Magyar onkologia, 2008, Volume: 52, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Imidazoles; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Xanthones	2008
Pharmacokinetic evaluation of axitinib. Expert opinion on drug metabolism & toxicology, 2012, Volume: 8, Issue:2 Topics: Animals; Axitinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Pancreatic Neoplasms; Protein Kinase Inhibitors; Thyroid Neoplasms	2012
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects]. Magyar onkologia, 2012, Volume: 56, Issue:3 Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays	2012
Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. Drugs of today (Barcelona, Spain : 1998), 2003, Volume: 39, Issue:3 Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Female; Humans; Indazoles; Lung Neoplasms; Male; Ovarian Neoplasms; Safety	2003
Lonidamine, a new approach to cancer therapy. Oncology, 1984, Volume: 41 Suppl 1 Topics: Abnormalities, Drug-Induced; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cell Division; Diuresis; Female; Indazoles; Kidney; Leukemia P388; Lung Neoplasms; Male; Mitochondria; Oxygen Consumption; Pregnancy; Pyrazoles; Sarcoma 180; Spermatogenesis	1984
New agents in non-small cell lung cancer. Cancer treatment reviews, 1984, Volume: 11, Issue:3 Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Indazoles; Lung Neoplasms; Male; Mice; Mitoxantrone; Triazines; Vinblastine; Vindesine	1984
Non small cell lung cancer and chemotherapy. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 1994, Volume: 49, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Fluorouracil; Humans; Indazoles; Lomustine; Lung Neoplasms; Methotrexate; Neoplasm Staging; Treatment Outcome	1994
Radiotherapy plus lonidamine in non-small cell lung cancer. Seminars in oncology, 1991, Volume: 18, Issue:2 Suppl 4 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms	1991

Trials

44 trial(s) available for indazoles and Cancer of Lung

Article	Year
JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer. Cancer, 2022, Jan-01, Volume: 128, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2022
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro-oncology, 2022, 10-03, Volume: 24, Issue:10 Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Child; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Young Adult	2022
The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer. Journal of managed care & specialty pharmacy, 2020, Volume: 26, Issue:8 Topics: Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA; Survival Rate; Treatment Outcome	2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses	2021
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rati Clinical lung cancer, 2021, Volume: 22, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; DNA Repair Enzymes; Germ-Line Mutation; Humans; Indazoles; Lung Neoplasms; Mesothelioma, Malignant; Mutation; Piperidines; Pleural Neoplasms; Prognosis; Prospective Studies	2021
Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications. ESMO open, 2021, Volume: 6, Issue:2 Topics: Adult; Benzamides; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms	2021
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021, Volume: 16, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Indazoles; Lung Neoplasms; Maintenance Chemotherapy; Ovarian Neoplasms; Piperidines	2021
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. ESMO open, 2021, Volume: 6, Issue:3 Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Patient Reported Outcome Measures; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Quality of Life	2021
Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS. Investigational new drugs, 2017, Volume: 35, Issue:4 Topics: Adult; Aged; Angiogenesis Inhibitors; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Tomography, X-Ray Computed; Treatment Outcome	2017
Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group. British journal of cancer, 2017, Jun-27, Volume: 117, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carboplatin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Pyrimidines; Small Cell Lung Carcinoma; Sulfonamides; Treatment Outcome	2017
A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer. Targeted oncology, 2017, Volume: 12, Issue:4 Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Receptors, Fibroblast Growth Factor; Stomach Neoplasms; Young Adult	2017
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-s European journal of cancer (Oxford, England : 1990), 2017, Volume: 86 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Sulfonamides; Treatment Outcome	2017
Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). British journal of cancer, 2018, 03-06, Volume: 118, Issue:5 Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Etoposide; Female; Humans; Indazoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Platinum; Progression-Free Survival; Pyrimidines; Small Cell Lung Carcinoma; Sulfonamides; Survival Analysis; Treatment Outcome	2018
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures. Cancer, 2018, 06-01, Volume: 124, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Placebos; Progression-Free Survival; Proteomics; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides	2018
Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:1 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Proportional Hazards Models; Treatment Outcome	2014
An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:12 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Pyrimidines; Sulfonamides; Survival Rate	2013
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies. British journal of cancer, 2014, May-27, Volume: 110, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indazoles; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Sulfonamides; Treatment Outcome	2014
A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC). Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Chemotherapy-Induced Febrile Neutropenia; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Japan; Leukopenia; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Severity of Illness Index; Thrombocytopenia; Tumor Burden	2014
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer, 2014, 09-01, Volume: 120, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Papillary; Diarrhea; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quality of Life; Thyroid Neoplasms; Treatment Outcome	2014
A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy. Lung cancer (Amsterdam, Netherlands), 2014, Volume: 86, Issue:2 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrimidines; Sulfonamides; Treatment Outcome	2014
Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Feb-10, Volume: 33, Issue:5 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Phenylurea Compounds; Receptors, Platelet-Derived Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor A	2015
Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064). European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides	2015
A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2016, Volume: 11, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Cisplatin; Female; Follow-Up Studies; Humans; Imidazoles; Indazoles; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neoplasm Staging; Pemetrexed; Pleural Neoplasms; Prognosis; Survival Rate	2016
Radiation Recall Dermatitis With Concomitant Dabrafenib and Pazopanib Therapy. JAMA dermatology, 2016, 05-01, Volume: 152, Issue:5 Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Diagnosis, Differential; Femoral Neoplasms; Fracture Fixation, Intramedullary; Fractures, Spontaneous; Humans; Imidazoles; Indazoles; Lung Neoplasms; Male; Middle Aged; Oximes; Pyrimidines; Radiodermatitis; Radiotherapy, Adjuvant; Sulfonamides	2016
A phase II study of axitinib in advanced neuroendocrine tumors. Endocrine-related cancer, 2016, Volume: 23, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Colonic Neoplasms; Female; Humans; Hypertension; Imidazoles; Indazoles; Intestinal Neoplasms; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Protein Kinase Inhibitors; Rectal Neoplasms; Thymus Neoplasms; Treatment Outcome	2016
Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-10, Volume: 27, Issue:23 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome	2009
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-20, Volume: 28, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Carcinoma, Renal Cell; Double-Blind Method; Female; Humans; Indazoles; International Agencies; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Placebos; Prognosis; Pyrimidines; Sulfonamides; Survival Rate; Treatment Outcome; Young Adult	2010
Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer research, 2010, Mar-15, Volume: 70, Issue:6 Topics: Aged; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; Cytokines; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Pyrimidines; Sulfonamides	2010
Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-01, Volume: 28, Issue:19 Topics: Administration, Oral; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Fatigue; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hypertension; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrimidines; Sulfonamides; Treatment Outcome	2010
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:8 Topics: Adenocarcinoma; Administration, Oral; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Indazoles; International Agencies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Phenylurea Compounds; Receptor Protein-Tyrosine Kinases; Salvage Therapy; Survival Rate; Treatment Outcome	2011
Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer, 2013, Jan-15, Volume: 119, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Diarrhea; Disease-Free Survival; Fatigue; Female; Humans; Indazoles; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Phenylurea Compounds; Treatment Outcome; Tumor Burden; Young Adult	2013
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. British journal of cancer, 2012, Oct-09, Volume: 107, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Imidazoles; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Treatment Outcome	2012
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. The Lancet. Oncology, 2007, Volume: 8, Issue:11 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Enzyme Inhibitors; Female; Humans; Imidazoles; Indazoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Treatment Outcome	2007
New agents in non-small cell lung cancer. Cancer treatment reviews, 1984, Volume: 11, Issue:3 Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Indazoles; Lung Neoplasms; Male; Mice; Mitoxantrone; Triazines; Vinblastine; Vindesine	1984
A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG) European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Indazoles; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Survival Analysis	1994
A prospective randomized comparison of radiation therapy plus lonidamine versus radiation therapy plus placebo as initial treatment of clinically localized but nonresectable nonsmall cell lung cancer. International journal of radiation oncology, biology, physics, 1994, Jul-30, Volume: 29, Issue:5 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Double-Blind Method; Humans; Indazoles; Lung Neoplasms; Male; Prospective Studies; Radiation-Sensitizing Agents	1994
A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer. Cancer, 1993, Sep-01, Volume: 72, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Tolerance; Female; Follow-Up Studies; Humans; Indazoles; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoplasm Staging; Pilot Projects; Remission Induction; Survival Rate	1993
Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial. Cancer, 1996, Jul-01, Volume: 78, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Epirubicin; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Vindesine	1996
Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Quality of Life; Vinblastine; Vindesine; Vinorelbine	1999
Lonidamine in non-small-cell lung cancer: a phase II study. Tumori, 1991, Feb-28, Volume: 77, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Humans; Indazoles; Liver; Lung Neoplasms; Male; Middle Aged	1991
Phase III trial with and without lonidamine in non-small cell lung cancer. Seminars in oncology, 1991, Volume: 18, Issue:2 Suppl 4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Neoplasm Staging; Prospective Studies; Remission Induction; Survival Rate; Time Factors; Vindesine	1991
Lonidamine versus polychemotherapy in advanced non-small-cell lung cancer. A preliminary analysis. Tumori, 1989, Feb-28, Volume: 75, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Mitomycins; Pyrazoles; Vinblastine	1989
Chemotherapy/radiation therapy plus/minus lonidamine in the treatment of non-small cell lung cancer (limited disease): preliminary results. Seminars in oncology, 1988, Volume: 15, Issue:6 Suppl 7 Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Pyrazoles; Random Allocation; Time Factors	1988
Phase II double-blind randomized study of lonidamine and radiotherapy in epidermoid carcinoma of the lung. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1987, Volume: 10, Issue:4 Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Double-Blind Method; Drug Evaluation; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Pyrazoles	1987

Other Studies

128 other study(ies) available for indazoles and Cancer of Lung

Article	Year
Development and application of a physiologically based pharmacokinetic model for entrectinib in rats and scale-up to humans: Route-dependent gut wall metabolism. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 146 Topics: Animals; Benzamides; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Models, Biological; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Rats	2022
Prioritizing the Catalytic Gatekeepers through Pan- Inhibitory Mechanism of Entrectinib against ALK, ROS1 and TRKA Tyrosine Kinases. Cell biochemistry and biophysics, 2022, Volume: 80, Issue:1 Topics: Anaplastic Lymphoma Kinase; Benzamides; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Tyrosine	2022
Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors. Cancer chemotherapy and pharmacology, 2022, Volume: 89, Issue:3 Topics: Adult; Benzamides; Carcinoma, Non-Small-Cell Lung; Child; Humans; Indazoles; Lung Neoplasms; Neoplasms, Second Primary; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases	2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 04-01, Volume: 28, Issue:7 Topics: Adult; Benzamides; Carcinoma, Non-Small-Cell Lung; Child; Humans; Indazoles; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins	2022
Two clinically distinct cases of infant hemispheric glioma carrying ZCCHC8:ROS1 fusion and responding to entrectinib. Neuro-oncology, 2022, 06-01, Volume: 24, Issue:6 Topics: Benzamides; Carrier Proteins; Glioma; Humans; Indazoles; Infant; Lung Neoplasms; Nuclear Proteins; Protein-Tyrosine Kinases; Proto-Oncogene Proteins	2022
Effectiveness of crizotinib versus entrectinib in Future oncology (London, England), 2022, Volume: 18, Issue:17 Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Treatment Outcome	2022
Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib. Molecular oncology, 2022, Volume: 16, Issue:10 Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Genomics; Humans; Indazoles; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins	2022
Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2022, Volume: 24, Issue:8 Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Nude; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Radiation Tolerance; Radiation-Sensitizing Agents	2022
Pazopanib restricts small cell lung cancer proliferation via reactive oxygen species-mediated endoplasmic reticulum stress. Thoracic cancer, 2022, Volume: 13, Issue:17 Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Endoplasmic Reticulum Stress; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Pyrimidines; Reactive Oxygen Species; Small Cell Lung Carcinoma; Sulfonamides	2022
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nature communications, 2019, 08-09, Volume: 10, Issue:1 Topics: Aminopyridines; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Crizotinib; Drug Development; Drug Resistance, Neoplasm; Humans; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Membrane Glycoproteins; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Receptor, trkB	2019
Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours. The Lancet. Oncology, 2020, Volume: 21, Issue:2 Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins	2020
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. The Lancet. Oncology, 2020, Volume: 21, Issue:2 Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Gene Fusion; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Progression-Free Survival; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Time Factors	2020
Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report. Journal of medical case reports, 2020, Jan-11, Volume: 14, Issue:1 Topics: Humans; Indazoles; Kidney Neoplasms; Lung Abscess; Lung Neoplasms; Male; Middle Aged; Pyrimidines; Sulfonamides	2020
YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells. European journal of pharmacology, 2020, May-05, Volume: 874 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Endocytosis; ErbB Receptors; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Lung Neoplasms; Protein Transport; Proteolysis	2020
Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells. Anticancer research, 2020, Volume: 40, Issue:4 Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mutation; Pleural Neoplasms; RNA, Small Interfering; Signal Transduction; Von Hippel-Lindau Tumor Suppressor Protein	2020
Effectiveness of pazopanib for local and lung metastases in Stewart-Treves syndrome. European journal of dermatology : EJD, 2020, Feb-01, Volume: 30, Issue:1 Topics: Aged; Angiogenesis Inhibitors; Duodenal Ulcer; Fatal Outcome; Female; Gastrointestinal Hemorrhage; Hemangiosarcoma; Humans; Indazoles; Lung Neoplasms; Lymphangiosarcoma; Pyrimidines; Stomach Ulcer; Sulfonamides	2020
Structural Insights into the Molecular Design of ROS1 Inhibitor for the Treatment of Non-Small Cell Lung Cancer (NSCLC). Current computer-aided drug design, 2021, Volume: 17, Issue:3 Topics: Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Design; Humans; Indazoles; Lung Neoplasms; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins	2021
Lorlatinib Salvages Central Nervous System-Only Relapse on Entrectinib in ROS1-Positive NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2020, Volume: 15, Issue:8 Topics: Aminopyridines; Benzamides; Central Nervous System; Humans; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles	2020
Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. Cell reports, 2020, 08-04, Volume: 32, Issue:5 Topics: Animals; Apoptosis; Bcl-2-Like Protein 11; Benzamides; Cell Line, Tumor; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Female; HEK293 Cells; Humans; Indazoles; Lung Neoplasms; Male; Mice, Inbred NOD; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Receptor, trkA	2020
Lorlatinib for the treatment of inflammatory myofibroblastic tumour with TPM4-ALK fusion following failure of entrectinib. Anti-cancer drugs, 2020, Volume: 31, Issue:10 Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Benzamides; Gene Fusion; Granuloma, Plasma Cell; Humans; Indazoles; Inflammation; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pyrazoles; Treatment Failure; Tropomyosin	2020
Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Cancer letters, 2020, 12-28, Volume: 495 Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Feedback, Physiological; Gefitinib; Gene Knockdown Techniques; Humans; Indazoles; Lung Neoplasms; Male; Mice; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Sulfonamides; Xenograft Model Antitumor Assays	2020
A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER". Journal of managed care & specialty pharmacy, 2020, Volume: 26, Issue:12 Topics: Benzamides; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines	2020
EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells. BMC cancer, 2020, Dec-04, Volume: 20, Issue:1 Topics: Adenosine; Adult; Aged; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Protein Kinase Inhibitors; Pyridones; RNA Interference; RNA, Neoplasm; RNA, Small Interfering; Signal Transduction	2020
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. Nature communications, 2021, 02-24, Volume: 12, Issue:1 Topics: Aminopyridines; Aniline Compounds; Animals; Apoptosis; Benzamides; Carbazoles; Cell Line; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Immunoblotting; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasm Recurrence, Local; Piperidines; Proto-Oncogene Proteins; Pyrazines; Pyrazoles; Receptor Protein-Tyrosine Kinases	2021
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 04-10, Volume: 39, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Young Adult	2021
PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021, Volume: 23, Issue:9 Topics: Animals; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Chemokine CCL5; Chemokine CXCL10; Chemoradiotherapy; DNA Breaks, Double-Stranded; Female; Fluorescent Antibody Technique; Genes, erbB-1; Humans; Immune System; Immunocompetence; Indazoles; Interferon Regulatory Factor-3; Interferon-beta; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Membrane Proteins; Mice; Mice, Inbred C57BL; Mutation; Nuclear Proteins; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Serine-Threonine Kinases; Radiation Tolerance; Radiation-Sensitizing Agents; Real-Time Polymerase Chain Reaction; TATA Box Binding Protein-Like Proteins; Tumor Stem Cell Assay	2021
[RENAL CELL CARCINOMA METASTASIS TO BLADDER DURING MOLECULAR TARGETED THERAPY WITH PAZOPANIB: REPORT OF TWO CASES]. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2020, Volume: 111, Issue:2 Topics: Aged; Carcinoma, Renal Cell; Combined Modality Therapy; Cystectomy; Fatal Outcome; Female; Humans; Indazoles; Kidney Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Nephrectomy; Pyrimidines; Sulfonamides; Treatment Outcome; Urinary Bladder Neoplasms	2020
An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model. Scientific reports, 2021, 04-21, Volume: 11, Issue:1 Topics: Adolescent; Animals; Antibiotics, Antineoplastic; Bone Neoplasms; Disease Models, Animal; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy, Combination; Everolimus; Female; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Osteosarcoma; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; TOR Serine-Threonine Kinases	2021
Different patterns of pneumothorax in patients with soft tissue tumors treated with pazopanib: A case series analysis. PloS one, 2021, Volume: 16, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Incidence; Indazoles; Lung; Lung Neoplasms; Male; Middle Aged; Pleura; Pneumothorax; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Soft Tissue Neoplasms; Sulfonamides; Time Factors	2021
Entrectinib-related myocarditis in a young female patient with metastatic non-small cell lung cancer. BMJ case reports, 2021, Jul-27, Volume: 14, Issue:7 Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indazoles; Lung Neoplasms; Middle Aged; Myocarditis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins	2021
A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib. Thoracic cancer, 2021, Volume: 12, Issue:18 Topics: Adenocarcinoma of Lung; Adult; Benzamides; Crizotinib; Female; Gene Rearrangement; Genomics; Humans; Indazoles; Lung Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins	2021
Pazopanib for second recurrence of osteosarcoma in pediatric patients. Pediatrics international : official journal of the Japan Pediatric Society, 2017, Volume: 59, Issue:8 Topics: Adolescent; Angiogenesis Inhibitors; Bone Neoplasms; Child; Female; Humans; Indazoles; Liver Neoplasms; Lung Neoplasms; Male; Osteosarcoma; Pyrimidines; Sulfonamides	2017
Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer. Journal of medicinal chemistry, 2017, 07-27, Volume: 60, Issue:14 Topics: Aminopyridines; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Databases, Chemical; Drug Design; Drug Screening Assays, Antitumor; Female; Heterografts; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Nude; Molecular Docking Simulation; Neoplasm Transplantation; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Rats, Sprague-Dawley; Signal Transduction; Stereoisomerism; Structure-Activity Relationship	2017
Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study Acta oncologica (Stockholm, Sweden), 2017, Volume: 56, Issue:12 Topics: Angiogenesis Inhibitors; Compassionate Use Trials; Disease-Free Survival; Female; Hemangiosarcoma; Humans; Indazoles; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged; Pyrimidines; Retrospective Studies; Sarcoma; Sarcoma, Synovial; Solitary Fibrous Tumors; Sulfonamides; Survival Rate; Time Factors; Uterine Neoplasms	2017
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. Cancer chemotherapy and pharmacology, 2017, Volume: 80, Issue:4 Topics: Cell Line, Tumor; Clone Cells; DNA Repair; Humans; Indazoles; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mutation; Phthalazines; Piperazines; Piperidines; Pleural Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Synthetic Lethal Mutations; Tumor Suppressor Proteins; Ubiquitin Thiolesterase	2017
Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma. Medical oncology (Northwood, London, England), 2017, Aug-29, Volume: 34, Issue:10 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chondrosarcoma; Disease-Free Survival; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasms, Connective and Soft Tissue; Pyrimidines; Ramucirumab; Retrospective Studies; Sulfonamides; Treatment Outcome	2017
KRIBB11 accelerates Mcl-1 degradation through an HSF1-independent, Mule-dependent pathway in A549 non-small cell lung cancer cells. Biochemical and biophysical research communications, 2017, 10-21, Volume: 492, Issue:3 Topics: Aminopyridines; Apoptosis; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Heat Shock Transcription Factors; HSP70 Heat-Shock Proteins; Humans; Indazoles; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Proteasome Endopeptidase Complex; Proteolysis; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases	2017
Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression. Nature communications, 2017, 11-28, Volume: 8, Issue:1 Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Down-Regulation; Female; Heterografts; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Lung Neoplasms; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mutation; Neoplasm Metastasis; Transfection; Ubiquitin-Protein Ligases; Ubiquitination	2017
Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting. World journal of urology, 2018, Volume: 36, Issue:3 Topics: Aged; Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Nephrectomy; Nivolumab; Probability; Prognosis; Proportional Hazards Models; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Sex Factors; Sulfonamides; Sunitinib; Survival Rate; Thrombocytosis	2018
CCAT1 stimulation of the symmetric division of NSCLC stem cells through activation of the Wnt signalling cascade. Gene therapy, 2018, Volume: 25, Issue:1 Topics: Axitinib; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Division; Genetic Therapy; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; MicroRNAs; Neoplastic Stem Cells; Prognosis; RNA, Long Noncoding; Wnt Signaling Pathway	2018
Micelle System Based on Molecular Economy Principle for Overcoming Multidrug Resistance and Inhibiting Metastasis. Molecular pharmaceutics, 2018, 03-05, Volume: 15, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Delayed-Action Preparations; Doxorubicin; Drug Carriers; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Hydrazines; Indazoles; Lung; Lung Neoplasms; MCF-7 Cells; Mice; Mice, Inbred BALB C; Micelles; Nanomedicine; Nitric Oxide; Rats; Rats, Sprague-Dawley; Tissue Distribution; Treatment Outcome; Vitamin E; Xenograft Model Antitumor Assays	2018
A-674563, a putative AKT1 inhibitor that also suppresses CDK2 activity, inhibits human NSCLC cell growth more effectively than the pan-AKT inhibitor, MK-2206. PloS one, 2018, Volume: 13, Issue:2 Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase 2; Down-Regulation; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Indazoles; Lung Neoplasms; Pyridines	2018
Improving therapy for patients with epidermal growth factor receptor-mutant lung cancer. Cancer, 2018, 06-01, Volume: 124, Issue:11 Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indazoles; Lung Neoplasms; Proteomics; Pyrimidines; Sulfonamides	2018
The Successful Treatment of Metastatic Extraosseous Ewing Sarcoma with Pazopanib. Internal medicine (Tokyo, Japan), 2018, Sep-15, Volume: 57, Issue:18 Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Bone Neoplasms; Female; Humans; Indazoles; Lung Neoplasms; Pyrimidines; Sarcoma, Ewing; Sulfonamides; Vaginal Neoplasms	2018
Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling. Cell death & disease, 2018, 07-24, Volume: 9, Issue:8 Topics: Animals; Aspirin; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Disease Models, Animal; Female; Indazoles; Lung Neoplasms; Macrophages; Mice; Mice, Inbred BALB C; NF-kappa B; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; RAW 264.7 Cells; Signal Transduction; Sulfonamides	2018
Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma. International heart journal, 2018, Sep-26, Volume: 59, Issue:5 Topics: Aged; Angiogenesis Inhibitors; Aortic Dissection; Axitinib; Carcinoma, Renal Cell; Heart Diseases; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vascular Endothelial Growth Factor A	2018
Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study. BMC cancer, 2018, Oct-01, Volume: 18, Issue:1 Topics: Adult; Aged; Case-Control Studies; Female; Humans; Indazoles; Logistic Models; Lung Neoplasms; Male; Middle Aged; Pneumothorax; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Factors; Sarcoma; Sulfonamides	2018
CFI-400945 is not a selective cellular PLK4 inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 2018, 11-13, Volume: 115, Issue:46 Topics: Humans; Indazoles; Indoles; Lung Neoplasms; Polyploidy; Protein Serine-Threonine Kinases	2018
Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2018, 11-13, Volume: 115, Issue:46 Topics: Humans; Indazoles; Indoles; Lung Neoplasms; Polyploidy	2018
Ex vivo culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics. British journal of pharmacology, 2019, Volume: 176, Issue:3 Topics: Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Inbred Strains; Mice, SCID; Neoplasms, Experimental; Neoplastic Cells, Circulating; Small Cell Lung Carcinoma; Structure-Activity Relationship; Sulfonamides; Tumor Cells, Cultured	2019
Targeting glucose and glutamine metabolism combined with radiation therapy in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2018, Volume: 126 Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Radiation; Enzyme Inhibitors; Glucose; Glutaminase; Glutamine; Glycolysis; Humans; Indazoles; Lung Neoplasms; Radiation Tolerance; X-Rays	2018
Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report. BMC pulmonary medicine, 2018, Dec-12, Volume: 18, Issue:1 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Brain Neoplasms; Carcinosarcoma; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Humans; Indazoles; Lung Neoplasms; Male; Meningeal Neoplasms; Neoplasm Staging; Pneumonectomy; Pyrimidines; Radiosurgery; Sulfonamides; Thrombocytopenia; Treatment Outcome	2018
Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma. European journal of medicinal chemistry, 2019, Feb-01, Volume: 163 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Discoidin Domain Receptor 2; Drug Discovery; Heterografts; Humans; Indazoles; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Receptor, Fibroblast Growth Factor, Type 1; Structure-Activity Relationship	2019
Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report. BMC nephrology, 2019, 01-03, Volume: 20, Issue:1 Topics: Aged; Amlodipine; Angiogenesis Inhibitors; Antihypertensive Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Diabetic Nephropathies; Dihydropyridines; Drug Substitution; Edema; Everolimus; Humans; Hypertension; Indazoles; Kidney Failure, Chronic; Lung Neoplasms; Male; Nephrotic Syndrome; Nivolumab; Pancreatic Neoplasms; Pancreaticoduodenectomy; Pneumonectomy; Protein Kinase Inhibitors; Pyrimidines; Sirolimus; Sulfonamides; Sunitinib	2019
Pazopanib Confers a Progression-free Survival in a Patient with Ewing's Sarcoma/Primitive Neuroectodermal Tumor of the Lung. Internal medicine (Tokyo, Japan), 2019, May-01, Volume: 58, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fatal Outcome; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive; Pneumonectomy; Progression-Free Survival; Pyrimidines; Sarcoma, Ewing; Sulfonamides; Treatment Outcome	2019
Development of Ultrasound-Triggered and Magnetic-Targeted Nanobubble System for Dual-Drug Delivery. Journal of pharmaceutical sciences, 2019, Volume: 108, Issue:3 Topics: A549 Cells; Administration, Inhalation; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Drug Compounding; Drug Delivery Systems; Ferrosoferric Oxide; Humans; Indazoles; Injections, Intralesional; Liposomes; Lung Neoplasms; Magnetic Phenomena; Mice; Nanoparticles; Nebulizers and Vaporizers; Pemetrexed; Pyrimidines; Sulfonamides; Tissue Distribution; Tumor Burden; Ultrasonic Waves; Xenograft Model Antitumor Assays	2019
Adjudin synergizes with paclitaxel and inhibits cell growth and metastasis by regulating the sirtuin 3-Forkhead box O3a axis in human small-cell lung cancer. Thoracic cancer, 2019, Volume: 10, Issue:4 Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Female; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Indazoles; Lung Neoplasms; Male; Mice; Paclitaxel; Sirtuin 3; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays	2019
Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nature communications, 2019, 05-17, Volume: 10, Issue:1 Topics: Animals; Antineoplastic Agents; Autophagy; Brain Neoplasms; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Delivery Systems; Electron Transport Complex I; Electron Transport Complex II; Female; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Mitochondria; Reactive Oxygen Species; Xenograft Model Antitumor Assays	2019
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer. Investigational new drugs, 2020, Volume: 38, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Indazoles; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras)	2020
A case of metastatic adamantinoma responding to treatment with pazopanib. Acta oncologica (Stockholm, Sweden), 2013, Volume: 52, Issue:6 Topics: Adamantinoma; Adult; Antineoplastic Agents; Female; Humans; Indazoles; Lung Neoplasms; Pyrimidines; Sulfonamides	2013
Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models. Molecular cancer therapeutics, 2013, Volume: 12, Issue:6 Topics: Aniline Compounds; Apoptosis; bcl-X Protein; Cell Line, Tumor; Enzyme Inhibitors; Genes, bcl-2; Humans; Indazoles; Lung Neoplasms; MAP Kinase Kinase Kinases; Molecular Targeted Therapy; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction; Sulfonamides	2013
Axitinib controlled metastatic renal cell carcinoma for 5 years. Japanese journal of clinical oncology, 2013, Volume: 43, Issue:7 Topics: Aged; Antineoplastic Agents; Asian People; Axitinib; Brain Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Protein Kinase Inhibitors; Seizures; Tomography, X-Ray Computed; Treatment Outcome	2013
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer research, 2013, Aug-15, Volume: 73, Issue:16 Topics: Animals; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Dimerization; Humans; Indazoles; Interleukin-3; Ligands; Lung Neoplasms; Mice; Mice, Nude; Mutation; NIH 3T3 Cells; Protein Kinase Inhibitors; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Sulfonamides	2013
A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Oncogene, 2013, Nov-21, Volume: 32, Issue:47 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Endonucleases; Enzyme Inhibitors; G2 Phase Cell Cycle Checkpoints; High-Throughput Screening Assays; Humans; Indazoles; Lung Neoplasms; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Isoforms; Rad51 Recombinase; RNA Interference; RNA, Small Interfering	2013
Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Oct-15, Volume: 19, Issue:20 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Gene Expression; Hepatocyte Growth Factor; Humans; Indazoles; Lung Neoplasms; Mice; Neoplasm Metastasis; Niacinamide; Oncogene Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-met; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays	2013
[Growth inhibition of combined pathway inhibitors on KRAS mutated non-small cell lung cancer cell line]. Zhonghua bing li xue za zhi = Chinese journal of pathology, 2013, Volume: 42, Issue:5 Topics: Apoptosis; bcl-2-Associated X Protein; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin B1; Cyclin D1; Dose-Response Relationship, Drug; Drug Synergism; Humans; Indazoles; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; ras Proteins; Signal Transduction; Sulfonamides	2013
Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma. Oncogene, 2014, Aug-21, Volume: 33, Issue:34 Topics: Animals; Carcinogenesis; Cell Line, Tumor; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Knockout Techniques; Humans; Indazoles; Lung Neoplasms; Lymphatic Metastasis; Melanoma, Experimental; Mice; Mice, Knockout; Mutation, Missense; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Pyrimidines; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Signal Transduction; Skin Neoplasms; Tissue Array Analysis	2014
Axitinib, a selective inhibitor of vascular endothelial growth factor receptor, exerts an anticancer effect in melanoma through promoting antitumor immunity. Anti-cancer drugs, 2014, Volume: 25, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Axitinib; Cell Proliferation; Female; Humans; Imidazoles; Indazoles; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays	2014
Statistical and practical considerations for clinical evaluation of predictive biomarkers. Journal of the National Cancer Institute, 2013, Nov-20, Volume: 105, Issue:22 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Indazoles; Interleukin-6; Kidney Neoplasms; Lung Neoplasms; Methylation; Molecular Targeted Therapy; Mutation; Neoplasms; Precision Medicine; Predictive Value of Tests; Pyrimidines; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sample Size; Sulfonamides; Temozolomide; Tumor Suppressor Proteins	2013
Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer research, 2014, Feb-01, Volume: 74, Issue:3 Topics: Amino Acid Sequence; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Enzyme Activation; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Indazoles; Lung Neoplasms; Mice; Niacinamide; Peptides; Proto-Oncogene Proteins c-met; Receptor Protein-Tyrosine Kinases; STAT3 Transcription Factor; Tumor Burden; Xenograft Model Antitumor Assays	2014
Complete pathologic response in soft tissue sarcoma lung metastases with pazopanib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:1 Topics: Angiogenesis Inhibitors; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Pyrimidines; Sarcoma; Sulfonamides; Tomography, X-Ray Computed	2014
Axitinib affects cell viability and migration of a primary foetal lung adenocarcinoma culture. Cancer investigation, 2014, Volume: 32, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Axitinib; Cell Movement; Cell Survival; Cisplatin; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Indazoles; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Protein Kinase Inhibitors; Radiography; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation; Vascular Endothelial Growth Factor A	2014
Dramatic response to pazopanib in a patient with metastatic malignant granular cell tumor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Nov-10, Volume: 32, Issue:32 Topics: Aged; Female; Granular Cell Tumor; Humans; Indazoles; Lung Neoplasms; Lymphatic Metastasis; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome	2014
Pazopanib combined with radiation: in vivo model of interaction. Cancer biotherapy & radiopharmaceuticals, 2014, Volume: 29, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Nude; Pyrimidines; Sulfonamides; Xenograft Model Antitumor Assays	2014
Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget, 2014, Jul-15, Volume: 5, Issue:13 Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Survival; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Repair; Female; Histones; Humans; Hydrogen Peroxide; Indazoles; Lung Neoplasms; Male; Microscopy, Fluorescence; Oxidants; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Rad51 Recombinase; Radiation-Sensitizing Agents; Tumor Stem Cell Assay; Tumor Suppressor Protein p53	2014
Pazopanib in metastatic osteosarcoma: significant clinical response in three consecutive patients. Acta oncologica (Stockholm, Sweden), 2014, Volume: 53, Issue:10 Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Female; Humans; Humerus; Indazoles; Lung Neoplasms; Male; Neoplasms, Radiation-Induced; Osteosarcoma; Pyrimidines; Skull Neoplasms; Sulfonamides; Young Adult	2014
What next? Choosing second-line therapy in progressive renal cell carcinoma. Oncology (Williston Park, N.Y.), 2014, Volume: 28, Issue:9 Topics: Aged; Angiogenesis Inhibitors; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Radiography; Spinal Neoplasms; Sulfonamides	2014
Acute aortic dissection in a patient with metastatic renal cell carcinoma treated with axitinib. Acta oncologica (Stockholm, Sweden), 2015, Volume: 54, Issue:4 Topics: Antineoplastic Agents; Aortic Aneurysm, Thoracic; Aortic Dissection; Axitinib; Carcinoma, Renal Cell; ErbB Receptors; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Sunitinib	2015
Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. BMC cancer, 2014, Oct-10, Volume: 14 Topics: Aldehyde Dehydrogenase 1 Family; Angiogenesis Inhibitors; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Indazoles; Isoenzymes; Liver Neoplasms; Lung Neoplasms; Mice, Inbred NOD; Neoadjuvant Therapy; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Retinal Dehydrogenase; Sarcoma; Sorafenib; Sulfonamides; Tissue Array Analysis; Xenograft Model Antitumor Assays	2014
Bronchopleural fistula arising after commencement of pazopanib for progressive sarcoma. ANZ journal of surgery, 2017, Volume: 87, Issue:7-8 Topics: Angiogenesis Inhibitors; Bronchial Fistula; Female; Humans; Indazoles; Lung Neoplasms; Middle Aged; Pleural Diseases; Pyrimidines; Sarcoma; Sulfonamides	2017
Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea. Cancer research and treatment, 2016, Volume: 48, Issue:1 Topics: Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indazoles; Kidney Neoplasms; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Pyrimidines; Republic of Korea; Sulfonamides; Treatment Outcome	2016
Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification. European urology, 2015, Volume: 68, Issue:1 Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Transitional Cell; Female; Gene Amplification; Humans; Indazoles; Lung Neoplasms; Mutation; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 3; Sulfonamides; Urinary Bladder Neoplasms	2015
Treatment with a Small Synthetic Compound, KMU-193, induces Apoptosis in A549 Human Lung Carcinoma Cells through p53 Up-Regulation. Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:14 Topics: Acetamides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Flow Cytometry; Humans; Indazoles; Lung Neoplasms; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2015
Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 2016, Volume: 14, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib	2016
Structure-Activity Relationship of Indole-Tethered Pyrimidine Derivatives that Concurrently Inhibit Epidermal Growth Factor Receptor and Other Angiokinases. PloS one, 2015, Volume: 10, Issue:9 Topics: Angiogenesis Inhibitors; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; ErbB Receptors; Human Umbilical Vein Endothelial Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Lung Neoplasms; Molecular Docking Simulation; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Structure-Activity Relationship; Sulfonamides; Vascular Endothelial Growth Factor A	2015
Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib. Lung cancer (Amsterdam, Netherlands), 2015, Volume: 90, Issue:2 Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Indazoles; Keratin-19; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Phenylurea Compounds	2015
Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis. American journal of physiology. Lung cellular and molecular physiology, 2015, Dec-15, Volume: 309, Issue:12 Topics: Animals; Axitinib; Cell Line, Tumor; Cell Proliferation; Chemokine CCL2; Disease Models, Animal; Female; Imidazoles; Indazoles; Lung; Lung Diseases; Lung Neoplasms; Lymphangioleiomyomatosis; Mice; Mice, Inbred C57BL; Mice, Nude; Nitric Oxide Synthase Type II; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Up-Regulation; Vascular Endothelial Growth Factor D	2015
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:12 Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Cohort Studies; Female; Gene Rearrangement; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Receptor, trkA	2015
Long-term survival following multidisciplinary treatment of metastatic sarcomatoid renal cell carcinoma: a case report. Journal of medical case reports, 2015, Nov-19, Volume: 9 Topics: Antineoplastic Agents; Axitinib; Biopsy; Bone Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Female; Humans; Imidazoles; Indazoles; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Radiotherapy; Survivors; Tomography, X-Ray Computed	2015
Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling. Gastroenterology, 2016, Volume: 150, Issue:2 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Crizotinib; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Hyaluronan Receptors; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mice, Nude; Mice, Transgenic; Mutation; Neoplasm Metastasis; Pancreatic Neoplasms; Peptides; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Rats; RNA, Messenger; Signal Transduction; Sulfonamides; Time Factors; Transfection; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2016
Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Brain Edema; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Lung Neoplasms; Middle Aged; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Radiation Injuries; Sulfonamides	2016
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis. European urology, 2016, Volume: 70, Issue:3 Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Registries; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome; Withholding Treatment	2016
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor. Journal of medicinal chemistry, 2016, Apr-14, Volume: 59, Issue:7 Topics: Administration, Oral; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Benzamides; Blood-Brain Barrier; Blotting, Western; Cell Membrane Permeability; Cell Proliferation; Crystallization; Crystallography, X-Ray; Dogs; Drug Discovery; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Nude; Mice, SCID; Microsomes, Liver; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Rats; Rats, Wistar; Receptor Protein-Tyrosine Kinases; Receptor, trkA; Receptor, trkB; Receptor, trkC; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2016
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. European urology, 2016, Volume: 70, Issue:6 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Remission Induction; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Tumor Burden	2016
An unexpected skin ulcer and soft tissue necrosis after the nonconcurrent combination of proton beam therapy and pazopanib: A case of myxofibrosarcoma. Auris, nasus, larynx, 2017, Volume: 44, Issue:4 Topics: Angiogenesis Inhibitors; Debridement; Fatal Outcome; Fibrosarcoma; Head and Neck Neoplasms; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Myxoma; Necrosis; Proton Therapy; Pyrimidines; Skin Ulcer; Soft Tissue Infections; Sulfonamides; Tomography, X-Ray Computed	2017
Inhibition of Notch and HIF enhances the antitumor effect of radiation in Notch expressing lung cancer. International journal of clinical oncology, 2017, Volume: 22, Issue:1 Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Lung Neoplasms; Mice, Nude; Molecular Targeted Therapy; Oligopeptides; Receptors, Notch; RNA, Small Interfering; Xenograft Model Antitumor Assays	2017
[Treatment of bilateral spontaneous pneumothorax during pazopanib therapy for pulmonary soft tissue sarcoma metastases. What to do when there is so few evidence?] Revue de pneumologie clinique, 2016, Volume: 72, Issue:5 Topics: Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Muscle Neoplasms; Pneumonectomy; Pneumothorax; Pyrimidines; Sarcoma; Sulfonamides	2016
A Case of Uterine Leiomyosarcoma with Long-Term Disease Control by Pazopanib. The Kobe journal of medical sciences, 2016, Jul-05, Volume: 62, Issue:2 Topics: Antineoplastic Agents; Female; Humans; Indazoles; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Sulfonamides; Tomography, X-Ray Computed; Uterine Neoplasms	2016
[Complete response to tyrosine kinase inhibitors in metastatic renal cancer. Report of four cases]. Archivos espanoles de urologia, 2016, Volume: 69, Issue:7 Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Remission Induction; Sunitinib	2016
In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC. Oncotarget, 2016, Nov-29, Volume: 7, Issue:48 Topics: A549 Cells; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azetidines; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Lung Neoplasms; Male; MAP Kinase Kinase Kinases; Middle Aged; Molecular Targeted Therapy; Mutation; Piperidines; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases	2016
Lack of effect of smoking status on axitinib pharmacokinetics in patients with non-small-cell lung cancer. Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Axitinib; Carcinoma, Non-Small-Cell Lung; Female; Humans; Imidazoles; Indazoles; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Protein Kinase Inhibitors; Smoking	2016
The Significant Effects of Pazopanib on Multiple Pulmonary Metastatic Lesions of Alveolar Soft Part Sarcoma: A Case Report. Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:3 Topics: Child; Female; Humans; Indazoles; Lung Neoplasms; Pyrimidines; Sarcoma, Alveolar Soft Part; Sulfonamides; Treatment Outcome	2017
Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor. Journal of medicinal chemistry, 2017, 03-23, Volume: 60, Issue:6 Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Indazoles; Lung; Lung Neoplasms; Mice; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors	2017
Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. Cancer research, 2009, May-15, Volume: 69, Issue:10 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Axitinib; Benzamides; Humans; Imatinib Mesylate; Imidazoles; Immunoglobulin Fc Fragments; Indazoles; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Transgenic; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1	2009
Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Targeted oncology, 2009, Volume: 4, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Axitinib; Disease Models, Animal; Drug Delivery Systems; Imidazoles; Indazoles; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2009
Bar the windows but open the door to randomization. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-01, Volume: 28, Issue:19 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Burkitt Lymphoma; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Neoplasms; Pyrimidines; Randomized Controlled Trials as Topic; Rituximab; Sulfonamides; Treatment Outcome	2010
The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells. Molecular medicine reports, 2012, Volume: 5, Issue:2 Topics: Apoptosis; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Enzyme Activation; G1 Phase Cell Cycle Checkpoints; Humans; Indazoles; Lung Neoplasms; Mitogen-Activated Protein Kinases; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases	2012
MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Investigational new drugs, 2012, Volume: 30, Issue:6 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Chemoradiotherapy; Female; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Nude; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Tumor Burden; Xenograft Model Antitumor Assays	2012
Drug approvals 2011: focus on companion diagnostics. Journal of the National Cancer Institute, 2012, Jan-18, Volume: 104, Issue:2 Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Brentuximab Vedotin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Approval; Female; Humans; Imidazoles; Immunoconjugates; Indazoles; Indoles; Ipilimumab; Lung Neoplasms; Male; Melanoma; Molecular Targeted Therapy; Neoplasms; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyridines; Quinazolines; Rare Diseases; Sulfonamides; Survival Analysis; United States; United States Food and Drug Administration; Vemurafenib	2012
FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:6 Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Fluorodeoxyglucose F18; Humans; Indazoles; Lung Neoplasms; Mice; Mice, SCID; Phenylurea Compounds; Positron-Emission Tomography; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays	2012
Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapy. Clinical & experimental metastasis, 2013, Volume: 30, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blotting, Western; Bone Neoplasms; Cell Movement; Cell Proliferation; Coculture Techniques; Immunoenzyme Techniques; Indazoles; Lung Neoplasms; Mice; Mice, Inbred C3H; Osteosarcoma; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A	2013
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Dec-15, Volume: 18, Issue:24 Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Comparative Genomic Hybridization; DNA Copy Number Variations; DNA Mutational Analysis; Drug Synergism; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Indazoles; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Signal Transduction; Sulfonamides; Transcriptome; Xenograft Model Antitumor Assays	2012
Ultralow doses of various drugs in chemotherapy of experimental tumors. Bulletin of experimental biology and medicine, 2003, Volume: 135 Suppl 7 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Indazoles; Leukemia P388; Lung Neoplasms; Melanoma; Mice; Mitomycin; Neoplasm Metastasis; Neoplasms, Experimental; Triazoles; Xenograft Model Antitumor Assays	2003
Synthesis and structure-activity relationships of novel pyrimido[1,2-b]indazoles as potential anticancer agents against A-549 cell lines. Bioorganic & medicinal chemistry letters, 2007, Jun-15, Volume: 17, Issue:12 Topics: Adenocarcinoma; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Humans; Indazoles; Lung Neoplasms; Pyrimidines; Quantitative Structure-Activity Relationship; Tubulin	2007
Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226. Biochemical pharmacology, 2008, Jan-15, Volume: 75, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Drug; G1 Phase; Humans; Indazoles; Lung Neoplasms; Mitogen-Activated Protein Kinases; Neoplasm Metastasis	2008
Phase II study of lonidamine in inoperable non-small-cell lung cancer. Oncology, 1984, Volume: 41 Suppl 1 Topics: Aged; Antineoplastic Agents; Digestive System; Drug Evaluation; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Muscles; Pyrazoles	1984
Cisplatin plus epirubicin and etoposide followed by irradiation plus lonidamine in stage III nonsmall cell lung cancer. Oncology, 1993, Volume: 50, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged	1993
[Antiemetic efficacy of granisetron in patients receiving 5-day continuous infusion of cisplatin]. Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:12 Topics: Adenocarcinoma; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Granisetron; Humans; Indazoles; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Nausea; Vindesine; Vomiting	1993
Selective effects of antileukotrienes on leukotriene and histamine release in human dispersed lung cells. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 1999, Volume: 48 Suppl 1 Topics: Histamine H1 Antagonists; Histamine Release; Humans; Hydroxyurea; Indazoles; Leukotriene Antagonists; Leukotrienes; Lipoxygenase Inhibitors; Lung; Lung Neoplasms; Pyrilamine; Quinolines	1999
An adriamycin-resistant subline is more sensitive than the parent human small cell lung cancer cell line to lonidamine. Anti-cancer drug design, 1992, Volume: 7, Issue:6 Topics: Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Humans; Indazoles; Lung Neoplasms; Tumor Cells, Cultured	1992
Single- and multiple dose pharmacokinetics of lonidamine in patients suffering from non-small-cell lung cancer. Arzneimittel-Forschung, 1991, Volume: 41, Issue:4 Topics: Adult; Aged; Aging; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, Gas; Chromatography, High Pressure Liquid; Female; Humans; Indazoles; Liver; Lung Neoplasms; Male; Middle Aged	1991
[Effects of lonidamine alone or in combination with radiotherapy on survival and metabolism in human and rodent cell lines]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1991, Volume: 167, Issue:12 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line; Cell Survival; Combined Modality Therapy; Cricetinae; Cricetulus; Humans; Hydrogen-Ion Concentration; Indazoles; Lung Neoplasms; Mice; Mitochondria; Oxidoreductases; Radiotherapy Dosage; Tetrazolium Salts; Tumor Cells, Cultured	1991
Clinical study and pharmacokinetics of lonidamine in advanced non-small cell lung cancer. European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged	1991
A phase II study on lonidamine combined with cisplatin and etoposide in the treatment of advanced non-small cell bronchogenic carcinoma (NSCBC). Journal of chemotherapy (Florence, Italy), 1990, Volume: 2, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Remission Induction	1990
The pharmacokinetics of oral lonidamine in breast and lung cancer patients. Seminars in oncology, 1991, Volume: 18, Issue:2 Suppl 4 Topics: Absorption; Administration, Oral; Aged; Antineoplastic Agents; Breast Neoplasms; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Tolerance; Female; Fluorescence; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Tablets; Time Factors	1991
Phase II study of lonidamine in non-small cell lung cancer: final report. British journal of cancer, 1990, Volume: 61, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrazoles	1990
Chronic administration of lonidamine in untreated non-small cell lung cancer of stage III M0-1. Chemotherapy, 1989, Volume: 35, Issue:1 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indazoles; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Pyrazoles	1989
Phase II study of lonidamine in patients with small cell carcinoma of the lung. Cancer treatment reports, 1987, Volume: 71, Issue:12 Topics: Adult; Aged; Carcinoma, Small Cell; Drug Evaluation; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Pyrazoles	1987